Literature DB >> 30689152

Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.

Bruria Hirsh Raccah1,2, Amihai Rottenstreich3, Netanel Zacks3, Ilan Matok2, Haim D Danenberg1, Arthur Pollak1, Yosef Kalish4.   

Abstract

Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Medical records of atrial fibrillation patients who underwent DOAC level testing during 2013-2017 were reviewed. The primary outcomes were drug levels under and above the expected steady-state range, and in the lowest and highest quartiles. Of 143 patients who underwent DOAC measurements, only 87 (60.8%) received the appropriate dose. Levels under the expected range and in the lowest quartile were found in 11.9% and 15.0% of patients treated with appropriate dosing compared to 21% and 41.5% of patients treated with inappropriately low dose. DOAC levels were above the expected range and in the highest quartile in 23.8% and 32.5% of patients treated with the appropriate dose compared to 7.1% and 9.4% treated with inappropriately low dose. In multivariate analysis, the administration of an appropriate DOAC dose was associated with a lower rate of DOAC in the lowest level (adjusted odds ratio [95% CI] 0.30 (0.12, 0.76), P = 0.011). On the other hand, appropriate dose was associated with drug levels in the highest quartile (odds ratio [95% CI] 3.77 (0.12, 0.76), P = 0.011). Treatment with inappropriately low DOAC dosing compared to appropriate dose is associated with lower DOAC levels. However, among those treated with appropriate dosing, a higher proportion had high DOAC levels above the expected range.

Entities:  

Keywords:  Direct-acting oral anticoagulants; Dose reduction; Drug levels; Monitoring; Real life

Mesh:

Substances:

Year:  2019        PMID: 30689152     DOI: 10.1007/s11239-019-01815-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  13 in total

1.  [Summary of the article: Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 1557-1559].

Authors:  Ewa Szczerba
Journal:  Kardiol Pol       Date:  2012       Impact factor: 3.108

2.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Europace       Date:  2010-10       Impact factor: 5.214

3.  Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.

Authors:  Martín Ruiz Ortiz; Javier Muñiz; Paula Raña Míguez; Inmaculada Roldán; Francisco Marín; María Asunción Esteve-Pastor; Angel Cequier; Manuel Martínez-Sellés; Vicente Bertomeu; Manuel Anguita
Journal:  Europace       Date:  2018-10-01       Impact factor: 5.214

4.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

Review 5.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

Review 7.  Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.

Authors:  John W Eikelboom; Daniel J Quinlan; Jack Hirsh; Stuart J Connolly; Jeffrey I Weitz
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

8.  Correlation between rivaroxaban (Xarelto) plasma activity, patient clinical variables and outcomes in a South African centre.

Authors:  S Louw; N P Saragas; P N Ferrao; T F Chirwa; B F Jacobson
Journal:  S Afr Med J       Date:  2016-09-08

9.  Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.

Authors:  Molly Howard; Andrew Lipshutz; Breanne Roess; Emily Hawes; Zachariah Deyo; Jena Ivey Burkhart; Stephan Moll; Betsy Bryant Shilliday
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

10.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

View more
  3 in total

1.  Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

Authors:  Ravi Sarode
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan.

Authors:  Masahiro Yasaka; Takeshi Yamashita; Masaharu Akao; Hirotsugu Atarashi; Takanori Ikeda; Yukihiro Koretsune; Ken Okumura; Wataru Shimizu; Hiroyuki Tsutsui; Kazunori Toyoda; Atsushi Hirayama; Takenori Yamaguchi; Satoshi Teramukai; Tetsuya Kimura; Jumpei Kaburagi; Atsushi Takita; Hiroshi Inoue
Journal:  BMJ Open       Date:  2021-03-08       Impact factor: 2.692

3.  Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.

Authors:  Diane Dreucean; Steffany N Nguyen; Kevin R Donahue; Eric Salazar; Melanie C Ruegger
Journal:  J Thromb Thrombolysis       Date:  2020-10-24       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.